Jiangsu Nhwa Pharmaceutical Co., LTD

002262

CNE100000CG8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
24.81 ^CNY	+3.94%		+6.57%	-8.52%

Apr. 25	Jiangsu Nhwa Pharmaceutical Co., LTD Approves Cash Dividend for 2023	CI
Apr. 19	Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Mr Wang Zeyu agreed to acquire 13% stake in Jiangsu Farever Pharma Co., Ltd. from Jiangsu Nhwa Pharmaceutical Co., LTD for CNY11.4673 million.

July 29, 2022

Mr Wang Zeyu agreed to acquire 13% stake in Jiangsu Farever Pharma Co., Ltd. from Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) for CNY11.4673 million on July 29, 2022. As on March 31, 2022 Jiangsu Farever Pharma Co., Ltd. total asset is CNY 126.369751 and total common equity CNY 69.392409 million.

Latest news about Jiangsu Nhwa Pharmaceutical Co., LTD

Jiangsu Nhwa Pharmaceutical Co., LTD Approves Cash Dividend for 2023	Apr. 24	CI
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 19	CI
Nhwa Pharma Gets Nod to Test NH103 Oxalate Tablets	Apr. 03	MT
Jiangsu Nhwa Pharmaceutical Co., Ltd Proposes Profit Distribution for 2023	Apr. 01	CI
Nhwa Pharmaceutical's 2023 Profit Climbs 15% as Revenue Rises 17%	Apr. 01	MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Monday Ahead of Data-Packed Week	Feb. 26	MT
Teva Pharmaceutical Investments Singapore Pte Ltd. and Jiangsu Nhwa Pharmaceutical Co., LTD Forge Strategic Partnership to Promote Patient Access to Austedo® in China	Feb. 26	CI
Nhwa Pharmaceutical Gets Green Light from US FDA After Addressing API Deficiencies	Dec. 21	MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Beijing Yihua M-Health Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Jiangsu Nhwa Pharmaceutical Co., LTD	23-10-24	CI
Jiangsu Nhwa Pharmaceutical Co., LTD(XSEC:002262) added to FTSE All-World Index	23-09-18	CI
Jiangsu Nhwa Pharma’s H1 Profit Jumps 21.7% as Revenue Rises 20%	23-07-31	MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-30	CI
Wang Zeyu cancelled the acquisition of 13% stake in Jiangsu Farever Pharma Co., Ltd. from Jiangsu Nhwa Pharmaceutical Co., LTD.	23-07-27	CI
Expected House Vote on Debt Ceiling Deal Weighs on Sentiment, Pushing US Equity Futures Lower	23-05-31	MT
Trevena Receives $3 Million Milestone Payment From Partner Jiangsu Nhwa Pharmaceutical	23-05-31	MT
Top Premarket Gainers	23-05-31	MT
Jiangsu Nhwa Pharmaceutical Co., Ltd. Receives Formal Approval from the National Medical Products Administration for OLINVYK	23-05-08	CI
Jiangsu Nhwa Pharmaceutical Co., Ltd Approves Cash Dividend for 2022, Payable on 28 April 2023	23-04-17	CI
Jiangsu Nhwa Pharma’s Q1 Profit Jumps 20.5% as Revenue Rises 19%; Shares Jump 5%	23-04-14	MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-13	CI
Jiangsu Nhwa Pharmaceutical Co., LTD Proposes Final Cash Dividend for 2022	23-03-20	CI
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Mr Wang Zeyu agreed to acquire 13% stake in Jiangsu Farever Pharma Co., Ltd. from Jiangsu Nhwa Pharmaceutical Co., LTD for CNY11.4673 million.	22-07-29	CI

Chart Jiangsu Nhwa Pharmaceutical Co., LTD

Duration

Period

Chart Jiangsu Nhwa Pharmaceutical Co., LTD

More charts

Company Profile

Jiangsu Nhwa Pharmaceutical Co., LTD is a China-based company principally engaged in the production and sales of pharmaceutical preparations. The Company offers its pharmaceutical products under four categories, which consist of anesthetic medicines, including midazolam injections and etomidate fat emulsion pharmaceutical preparations injections; psychiatric medicines, including risperidone tablets and others; neurological medicines, including gabapentin capsules and others; bulk drugs, including fenofibrate and miconazole nitrate. The Company is also engaged in the pharmaceuticals trading business. Through its subsidiaries, the Company is also engaged in the Internet medical businesses. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Jiangsu Nhwa Pharmaceutical Co., LTD

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.81 CNY

Average target price

32.21 CNY

Spread / Average Target

+29.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JIANGSU NHWA PHARMACEUTICAL CO., LTD	-8.52%	3.45B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Jiangsu Nhwa Pharmaceutical Co., LTD

Equities

002262

CNE100000CG8

Pharmaceuticals

Mr Wang Zeyu agreed to acquire 13% stake in Jiangsu Farever Pharma Co., Ltd. from Jiangsu Nhwa Pharmaceutical Co., LTD for CNY11.4673 million.

EPS Revisions